Zyversa Therapeutics, Inc.
SEC CIK 1859007 · ZVSA · last insider filing 2025-07-16
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Cashmere Karen A. | Director · Chief Commercial Officer | filed 2022 - 2025 |
| Glover Steve C | Director · Chief Executive Officer | filed 2022 - 2025 |
| Freitag Gregory Gene | Director | filed 2023 - 2025 |
| Finizio Robert G | Director | filed 2022 - 2025 |
| Sapirstein James | Director | filed 2023 - 2025 |
| Park Min-Chul | Director | filed 2022 - 2025 |
| Rupalla Katrin | Director | filed 2023 - 2023 |
| O'Connor Daniel J. | Director · Chief Executive Officer | filed 2021 - 2022 |
| Briones David S. | Director · Chief Financial Officer | filed 2021 - 2022 |
| Mehra Raj | Director | filed 2021 - 2022 |
| Twitty Christopher | Director | filed 2021 - 2022 |
| Skalicky Gregory | Director | filed 2021 - 2022 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Wolfe Peter | Chief Financial Officer | filed 2022 - 2025 |
| Guzman Pablo A. | Chief Medical Officer | filed 2023 - 2025 |
| Labella Nicholas A. Jr. | Chief Scientific Officer | filed 2022 - 2022 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.